Interaction of antimicrobial peptide s-thanatin with lipopolysaccharide in vitro and in an experimental mouse model of septic shock caused by a multidrug-resistant clinical isolate of Escherichia coli

International Journal of Antimicrobial Agents

Volumn 35, Issue 3, 2010, Pages 250-254

  Wu, Guoqiu ^a   Fan, Xiaobo ^b   Li, Linxian ^b   Wang, Hailiang ^a   Ding, Jiaxuan ^b   Hongbin, Wu ^b   Zhao, Rui ^b   Gou, Lixia ^a   Shen, Zilong ^b   Xi, Tao ^b  

^a SOUTHEAST UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antimicrobial peptide; Lipopolysaccharide; Multidrug resistance

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; ERTAPENEM; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; S THANATIN; SODIUM CHLORIDE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG SYNTHESIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ASCITIC FLUID; BLOOD; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDOTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; INJECTIONS, INTRAPERITONEAL; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED ICR; MICROBIAL VIABILITY; PEPTIDES, CYCLIC; PROTEIN BINDING; SHOCK, SEPTIC; SURVIVAL ANALYSIS;

EID: 73549123648     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.11.009     Document Type: Article

References (27)

1. Charrel R.N., Pages J.M., De Micco P., and Mallea M. Prevalence of outer membrane porin alteration in β-lactam-antibiotic-resistant Enterobacter aerogenes. Antimicrob Agents Chemother 40 (1996) 2854-2858
2. Cirioni O., Giacometti A., Ghiselli R., Mocchegiani F., Fineo A., Orlando F., et al. Single-dose intraperitoneal magainins improve survival in a Gram-negative-pathogen septic shock rat model. Antimicrob Agents Chemother 46 (2002) 101-104
3. David S.A. Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules. J Mol Recognit 14 (2001) 370-387
4. David S.A., Awasthi S.K., and Balaram P. The role of polar and facial amphipathic character in determining lipopolysaccharide-binding properties in synthetic cationic peptides. J Endotoxin Res 6 (2000) 249-256
5. Fehlbaum P., Bulet P., Chernysh S., Briand J.P., Roussel J.P., Letellier L., et al. Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Proc Natl Acad Sci USA 93 (1996) 1221-1225
6. Ghiselli R., Giacometti A., Cirioni O., Circo R., Mocchegiani F., Skerlavaj B., et al. Neutralization of endotoxin in vitro and in vivo by Bac7(1-35), a proline-rich antibacterial peptide. Shock 19 (2003) 577-581
7. Giacometti A., Cirioni O., Ghiselli R., Mocchegiani F., Del Prete M.S., Viticchi C., et al. Potential therapeutic role of cationic peptides in three experimental models of septic shock. Antimicrob Agents Chemother 46 (2002) 2132-2136
8. Gough M., Hancock R.E., and Kelly N.M. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 64 (1996) 4922-4927
9. Hancock R.E., and Scott M.G. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci USA 97 (2000) 8856-8861
10. Hwang Y.H., Park B.K., Lim J.H., Kim M.S., Park S.C., Hwang M.H., et al. Lipopolysaccharide-binding and neutralizing activities of surfactin C in experimental models of septic shock. Eur J Pharmacol 556 (2007) 166-171
11. Jiang Z., Hong Z., Guo W., Xiaoyun G., Gengfa L., Yongning L., et al. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo. Int Immunopharmacol 4 (2004) 527-537
12. Khownium K., Wood S.J., Miller K.A., Balakrishna R., Nguyen T.B., Kimbrell M.R., et al. Novel endotoxin-sequestering compounds with terephthalaldehyde-bis-guanylhydrazone scaffolds. Bioorg Med Chem Lett 16 (2006) 1305-1308
13. Wu G.Q., Ding J.X., Li L.X., Wang H.L., Zhao R., and Shen Z.L. Activity of the antimicrobial peptide and thanatin analog s-thanatin on clinical isolates of Klebsiella pneumoniae resistant to conventional antibiotics with different structures. Curr Microbiol 59 (2009) 147-153
14. Mandard N., Sodano P., Labbe H., Bonmatin J.M., Bulet P., Hetru C., et al. Solution structure of thanatin, a potent bactericidal and fungicidal insect peptide, determined from proton two-dimensional nuclear magnetic resonance data. Eur J Biochem 256 (1998) 404-410
15. Michie H.R., Manogue K.R., Spriggs D.R., Revhaug A., O'Dwyer S., Dinarello C.A., et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318 (1988) 1481-1486
16. Nagaoka I., Hirota S., Niyonsaba F., Hirata M., Adachi Y., Tamura H., et al. Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin Diagn Lab Immunol 9 (2002) 972-982
17. Pittet J.F., Morel D.R., Hemsen A., Gunning K., Lacroix J.S., Suter P.M., et al. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg 213 (1991) 261-264
18. Pradel E., and Pages J.M. The AcrAB-TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen Enterobacter aerogenes. Antimicrob Agents Chemother 46 (2002) 2640-2643
19. Rosenfeld Y., Papo N., and Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J Biol Chem 281 (2006) 1636-1643
20. Scott M.G., Yan H., and Hancock R.E. Biological properties of structurally related α-helical cationic antimicrobial peptides. Infect Immun 67 (1999) 2005-2009
21. Scott M.G., Vreugdenhil A.C., Buurman W.A., Hancock R.E., and Gold M.R. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol 164 (2000) 549-553
22. Wood S.J., Miller K.A., and David S.A. Anti-endotoxin agents. 1. Development of a fluorescent probe displacement method optimized for the rapid identification of lipopolysaccharide-binding agents. Comb Chem High Throughput Screen 7 (2004) 239-249
23. Cohen J. Non-antibiotic strategies for sepsis. Clin Microbiol Infect 15 (2009) 302-307
24. Saraceno R., and Chimenti S. How to manage infections in the era of biologics?. Dermatol Ther 21 (2008) 180-186
25. Wu G.Q., Li L.X., Ding J.X., Wen L.Z., and Shen Z.L. High-level expression and novel purification strategy of recombinant thanatin analog in Escherichia coli. Curr Microbiol 57 (2008) 95-101
26. Wu G., Ding J., Li H., Li L., Zhao R., Shen Z., et al. Effects of cations and pH on antimicrobial activity of thanatin and s-thanatin against Escherichia coli ATCC25922 and B. subtilis ATCC 21332. Curr Microbiol 57 (2008) 552-557
27. Jenssen H., Hamill P., and Hancock R.E. Peptide antimicrobial agents. Clin Microbiol Rev 19 (2006) 491-511